SS Innovations International (NASDAQ:SSII – Get Free Report) and Pulmonx (NASDAQ:LUNG – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings and profitability.
Analyst Recommendations
This is a summary of recent ratings and target prices for SS Innovations International and Pulmonx, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| SS Innovations International | 1 | 0 | 0 | 0 | 1.00 |
| Pulmonx | 1 | 0 | 3 | 0 | 2.50 |
SS Innovations International presently has a consensus target price of $7.00, suggesting a potential upside of 195.36%. Pulmonx has a consensus target price of $7.67, suggesting a potential upside of 293.16%. Given Pulmonx’s stronger consensus rating and higher possible upside, analysts clearly believe Pulmonx is more favorable than SS Innovations International.
Insider and Institutional Ownership
91.0% of Pulmonx shares are owned by institutional investors. 7.5% of Pulmonx shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares SS Innovations International and Pulmonx’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| SS Innovations International | -23.73% | -26.77% | -15.01% |
| Pulmonx | -55.03% | -96.66% | -38.32% |
Risk and Volatility
SS Innovations International has a beta of -1.79, suggesting that its stock price is 279% less volatile than the S&P 500. Comparatively, Pulmonx has a beta of 0.33, suggesting that its stock price is 67% less volatile than the S&P 500.
Valuation and Earnings
This table compares SS Innovations International and Pulmonx”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| SS Innovations International | $42.49 million | 11.18 | -$12.13 million | ($0.06) | -39.50 |
| Pulmonx | $90.50 million | 0.93 | -$54.00 million | ($1.16) | -1.68 |
SS Innovations International has higher earnings, but lower revenue than Pulmonx. SS Innovations International is trading at a lower price-to-earnings ratio than Pulmonx, indicating that it is currently the more affordable of the two stocks.
Summary
Pulmonx beats SS Innovations International on 7 of the 13 factors compared between the two stocks.
About SS Innovations International
AVRA Medical Robotics, Inc. develops and manufactures medical surgical devices. The company has a research agreement with the University of Central Florida to develop navigation and control technologies with applications in medical robotics. The company was formerly known as AVRA Surgical Microsystems, Inc. and changed its name to AVRA Medical Robotics, Inc. in November 2015. AVRA Medical Robotics, Inc. was founded in 2015 and is based in Orlando, Florida.
About Pulmonx
Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
Receive News & Ratings for SS Innovations International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SS Innovations International and related companies with MarketBeat.com's FREE daily email newsletter.
